[Abstract] This protocol was developed to generate chimeric mice in which T lymphocytes could be stratified by age on the basis of congenic marker expression. The conditioning drug busulfan is used to ablate host haematopoietic stem cells while leaving the peripheral immune system intact. Busulfan treatment is followed by bone marrow transplantation (BMT), with T-cell depleted donor bone marrow bearing a different congenic marker (CD45.2) to that of the host mouse (CD45.1). New cell production post-BMT can thus be tracked by measuring the fraction of CD45.2 + cells over time within a population of interest (Hogan et al., 2015; Gossel et al., 2017) .
[Background] Bone marrow chimeras are a valuable tool for studying immune system development and function. Typically, chimeras are generated by irradiation of host mice followed by transplantation with donor bone marrow. Irradiation causes considerable damage to the haematopoietic system, and full immune reconstitution is delayed by weeks to months post-transplant (Fry and Mackall, 2005) . The resulting period of lymphopenia drives spontaneous proliferation of naïve T cells and the acquisition of a memory-like phenotype (Goldrath et al., 2004) . To avoid the perturbation of immune homeostasis caused by irradiation, we turned our attention to the conditioning drug busulfan. Busulfan is an alkylating agent that is toxic to haematopoietic stem cells (HSC) but does not deplete circulating lymphocytes (Westerhof et al., 2000; Hsieh et al., 2007) . Following busulfan conditioning and bone marrow transplantation (BMT), chimeras are indistinguishable from untreated controls: they have normal numbers of naïve and memory CD4 and CD8 T cells, and these cells express normal levels of the proliferation marker Ki67 (Hogan et al., 2015; Gossel et al., 2017) . Therefore, busulfan conditioning allows induction of chimerism while preserving peripheral immune homeostasis. By using donor bone marrow bearing a congenic marker, it is possible to distinguish host-or donor-origin cells by flow cytometry. While HSC replacement is never absolute, emergence of donor origin cells can be used as an accurate proxy for de novo haematopoetic development since BMT, thereby allowing cells within a population to be stratified by age on the basis of congenic marker expression. Note: This must be prepared fresh each day and cannot be stored. 
Day -1: Repeat
Steps A1-A4 for a second injection of busulfan. The final dose of busulfan in each mouse is thus 20 μg/g, delivered as two doses of 10 μg/g 24 h apart.
Note: Mice remain healthy and alert after busulfan injection. HSC are depleted within 24 h after busulfan treatment (Westerhof et al., 2000) .
B. Preparation of T cell depleted donor CD45.2 bone marrow (Day 0)
Note: Cell suspensions can be prepared on the bench; a laminar flow hood is not required. 2. By 6 weeks post-BMT, we typically see that the fraction of cells in the thymus that are donorderived has stabilised at approximately 90%, and this is maintained up to one year post-BMT.
The extent of stem cell replacement and therefore chimerism in progenitor populations varies between mice, reflecting variability in the ablation of host stem cells in the bone marrow. Thus the output of de novo generated T cells from the thymus is chimeric with respect to donor and host. To account for this, we measure the donor: host ratio within the thymus CD4 + CD8 + DP population of all mice as an accurate proxy for stem cell replacement in the bone marrow. With 
